InMed Pharmaceuticals (INM) Revenue (2021 - 2025)

InMed Pharmaceuticals has reported Revenue for 5 years, with the latest figure at $820188.0 in Q4 2025.

• For the quarter ending Q4 2025, Revenue fell 26.22% year-over-year to $820188.0; the trailing twelve-month figure through Dec 2025 stood at $4.5 million (down 6.73% YoY), and the FY2025 full-year result was $4.9 million, up 7.5% from the prior year.
• Revenue for Q4 2025 stood at $820188.0, down from $1.1 million in the prior quarter.
• The five-year high for Revenue was $2.3 million in Q2 2023, with the low at $265092.0 in Q4 2021.
• Historically, Revenue has averaged $982686.4 across 5 years, with a median of $1.1 million in 2024.
• Annual changes were most pronounced in 2023 — Revenue soared 348.96% — and 2024, when it tumbled 44.48%.
• InMed Pharmaceuticals' Revenue stood at $265092.0 in 2021, then jumped by 77.22% to $469783.0 in 2022, then soared by 163.99% to $1.2 million in 2023, then fell by 10.36% to $1.1 million in 2024, then dropped by 26.22% to $820188.0 in 2025.
• The last three Revenue figures came in at $820188.0 (Q4 2025), $1.1 million (Q3 2025), and $1.3 million (Q2 2025), per Business Quant data.